López Grancha, Matilde Author
Vulnerability of long-term neurotoxicity of chlorpyrifos:: effect on schedule-induced polydipsia and a delay discounting task
- Cardona D.
- López-Grancha M.
- López-Crespo G.
- Nieto-Escamez F.
- Sánchez-Santed F.
- Flores P.
PSYCHOPHARMACOLOGY - 1/11/2006
- JCR Quartile: Q1 (2006)
- SJR Quartile: Q1
- JCR Impact Factor: 3.625 (2022)
- Category normalized Impact: 0.802 (2006)
- CiteScore: 6 (2020)
- SJR: 1.892 (2006
- SNIP: 1.145 (2006
- SJR Categories: Pharmacology (Q1)
- Scopus
- ORCID
- Web of Science
The selective reversible FAAH inhibitor, SSR411298, restores the development of maladaptive behaviors to acute and chronic stress in rodents
- Griebel G.
- Stemmelin J.
- Lopez-Grancha M.
- Fauchey V.
- Slowinski F.
- Pichat P.
- Dargazanli G.
- Abouabdellah A.
- Cohen C.
- Bergis O.
Scientific Reports - 1/12/2018
- SJR Quartile: Q1
- JCR Impact Factor: 4.011 (2018)
- JCR 5-year Impact Factor: 4.525
- JCR Categories: MULTIDISCIPLINARY SCIENCES
- SJR Categories: Multidisciplinary (Q1)
The selective GSK3 inhibitor, SAR502250, displays neuroprotective activity and attenuates behavioral impairments in models of neuropsychiatric symptoms of Alzheimer’s disease in rodents
- Griebel G.
- Stemmelin J.
- Lopez-Grancha M.
- Boulay D.
- Boquet G.
- Slowinski F.
- Pichat P.
- Beeské S.
- Tanaka S.
- Mori A.
- Fujimura M.
- Eguchi J.
Scientific Reports - 1/12/2019
- SJR Quartile: Q1
- JCR Impact Factor: 3.998 (2019)
- JCR 5-year Impact Factor: 4.576
- JCR Categories: MULTIDISCIPLINARY SCIENCES
- SJR Categories: Multidisciplinary (Q1)
The neurokinin NK2 antagonist, saredutant, ameliorates stress-induced conditions without impairing cognition
- Rogacki N.
- Lopez-Grancha M.
- Naimoli V.
- Potestio L.
- Stevens R.
- Pichat P.
- Bergis O.
- Cohen C.
- Varty G.
- Griebel G.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR - 1/5/2011
- SJR Quartile: Q1
- JCR Impact Factor: 2.532 (2011)
- CiteScore: 4.7 (2020)
- SJR: 1.138 (2011
- SNIP: 0.903 (2011
- JCR 5-year Impact Factor: 2.77
- JCR Categories: BEHAVIORAL SCIENCES
- SJR Categories: Pharmacology (Q1); Toxicology (Q1); Behavioral Neuroscience (Q2); Biochemistry (Q2); Biological Psychiatry (Q2); Clinical Biochemistry (Q2)
Tetravalent Bispecific Tandem Antibodies Improve Brain Exposure and Efficacy in an Amyloid Transgenic Mouse Model
- Do T.M.
- Capdevila C.
- Pradier L.
- Blanchard V.
- Lopez-Grancha M.
- Schussler N.
- Steinmetz A.
- Beninga J.
- Boulay D.
- Dugay P.
- Verdier P.
- Aubin N.
- Dargazanli G.
- Chaves C.
- Genet E.
- Lossouarn Y.
- Loux C.
- Michoux F.
- Moindrot N.
- Chanut F.
- Gury T.
- Eyquem S.
- Valente D.
- Bergis O.
- Rao E.
- Lesuisse D.
Molecular Therapy - Methods and Clinical Development - 11/12/2020
- JCR Impact Factor: 6.698 (2020)
- JCR 5-year Impact Factor: 5.76
- JCR Categories: MEDICINE, RESEARCH & EXPERIMENTAL
Systemic immune-checkpoint blockade with anti-PD1 antibodies does not alter cerebral amyloid-? burden in several amyloid transgenic mouse models
- Latta-Mahieu M.
- Elmer B.
- Bretteville A.
- Wang Y.
- Lopez-Grancha M.
- Goniot P.
- Moindrot N.
- Ferrari P.
- Blanc V.
- Schussler N.
- Brault E.
- Roudières V.
- Blanchard V.
- Yang Z.Y.
- Barneoud P.
- Bertrand P.
- Roucourt B.
- Carmans S.
- Bottelbergs A.
- Mertens L.
- Wintmolders C.
- Larsen P.
- Hersley C.
- McGathey T.
- Racke M.M.
- Liu L.
- Lu J.
- O'Neill M.J.
- Riddell D.R.
- Ebneth A.
- Nabel G.J.
- Pradier L.
GLIA - 1/3/2018
- SJR Quartile: Q1
- JCR Impact Factor: 5.829 (2018)
- CiteScore: 10.7 (2020)
- SJR: 2.855 (2018
- SNIP: 1.365 (2018
- JCR 5-year Impact Factor: 6.389
- JCR Categories: NEUROSCIENCES
- SJR Categories: Cellular and Molecular Neuroscience (Q1); Neurology (Q1)
Stimulation of the beta(3)-adrenoceptor as a novel treatment strategy for anxiety and depressive disorders
- Stemmelin J.
- Cohen C.
- Terranova J.
- Lopez-Grancha M.
- Pichat P.
- Bergis O.
- Decobert M.
- Santucci V.
- Françon D.
- Alonso R.
- Stahl S.
- Keane P.
- Avenet P.
- Scatton B.
- Le Fur G.
- Griebel G.
Neuropsychopharmacology - 1/2/2008
- SJR Quartile: Q1
- CiteScore: 11.8 (2020)
- SJR: 3.385 (2008
- SNIP: 1.534 (2008
- SJR Categories: Pharmacology (Q1); Psychiatry and Mental Health (Q1)
Selective blockade of the hydrolysis of the endocannabinoid 2-arachidonoylglycerol impairs learning and memory performance while producing antinociceptive activity in rodents
- Griebel G.
- Pichat P.
- Beeske S.
- Leroy T.
- Redon N.
- Jacquet A.
- Françon D.
- Bert L.
- Even L.
- Lopez-Grancha M.
- Tolstykh T.
- Sun F.
- Yu Q.
- Brittain S.
- Arlt H.
- He T.
- Zhang B.
- Wiederschain D.
- Bertrand T.
- Houtmann J.
- Rak A.
- Vallee F.
- Michot N.
- Auge F.
- Menet V.
- Bergis O.
- George P.
- Avenet P.
- Mikol V.
- Didier M.
- Escoubet J.
Scientific Reports - 6/1/2015
- SJR Quartile: Q1
- JCR Impact Factor: 5.228 (2015)
- JCR 5-year Impact Factor: 5.525
- JCR Categories: MULTIDISCIPLINARY SCIENCES
- SJR Categories: Multidisciplinary (Q1)
SAR110894, a potent histamine H3-receptor antagonist, displays procognitive effects in rodents
- Griebel G.
- Pichat P.
- Pruniaux M.
- Beeské S.
- Lopez-Grancha M.
- Genet E.
- Terranova J.
- Castro A.
- Sánchez J.
- Black M.
- Varty G.
- Weiner I.
- Arad M.
- Barak S.
- De Levie A.
- Guillot E.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR - 1/8/2012
- SJR Quartile: Q1
- JCR Impact Factor: 2.608 (2012)
- CiteScore: 4.7 (2020)
- SJR: 1.197 (2012
- SNIP: 0.91 (2012
- JCR 5-year Impact Factor: 2.848
- JCR Categories: BEHAVIORAL SCIENCES
- SJR Categories: Clinical Biochemistry (Q1); Pharmacology (Q1); Toxicology (Q1); Behavioral Neuroscience (Q2); Biochemistry (Q2); Biological Psychiatry (Q2)
SAR110894, a potent histamine H3-receptor antagonist, displays disease-modifying activity in a transgenic mouse model of tauopathy
- Delay-Goyet P.
- Blanchard V.
- Schussler N.
- Lopez-Grancha M.
- Ménager J.
- Mary V.
- Sultan E.
- Buzy A.
- Guillemot J.
- Stemmelin J.
- Bertrand P.
- Rooney T.
- Pradier L.
- Barnéoud P.
Alzheimer's and Dementia: Translational Research and Clinical Interventions - 1/11/2016
- SJR Quartile: Q2
- SJR Categories: Neurology (clinical) (Q2); Psychiatry and Mental Health (Q2)
This author has no books, chapters or theses.
This author has no conferences.
This author has no patents.
This author has no reports or other types of publications.
Contact info
Email: mlopezg@ual.es
h index
Scopus: 12
Web of Science: 6
i10 index
Scopus: 12
Web of Science: 5
Author profiles
-
Scopus Author ID
-
Dialnet id
Research projects at UAL
-
Acronym P06-CTS-01350Since: April 12, 2007Until: April 11, 2010Funded by: JUNTAFunding / grant amount: 201,027.62 EURRole: Investigador
-
Acronym BSO2002-04322-C02-01Since: November 1, 2002Until: October 31, 2005Funded by: MECFunding / grant amount: 27,600.00 EURRole: Investigador